TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06728059

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Automated Insulin Delivery Adaptive NETwork (AIDANET)
Description: Group A participants will use the AIDANET system at home for 7 days/6 nights. They will continue use of AIDANET system for 18 hours during the hotel session and then use AIDANET+BPS_RL for 18 hours during the hotel session.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AIDANET+ BPS_RL→AIDANET
Description: Group B participant will use the AIDANET+BPS_RL system for 18 hours during the hotel session and will then use AIDANET system for 18 hours during the hotel session. They will continue to use AIDANET+BPS_RL system at home for 7 days/6 night and then use the AIDANET system at home for 7 days/6 nights.
Study: NCT06727617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: intravenous infusion of 300 mg, administered every 3 weeks as one cycle, on the first day of each cycle, with a maximum treatment duration of 2 years (up to 35 treatment cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Cisplatin: Administered by intravenous infusion during concurrent chemoradiotherapy at a dose of 30-40 mg/m² once weekly for only 5-6 treatment cycles; during sequential chemoradiotherapy, administered at 60-75 mg/m² on the first and second days of each cycle, once every 3 weeks (21 days) for only 4 treatment cycles.~Paclitaxel: Nab-paclitaxel administered by intravenous infusion at a dose of 135-175 mg/m² on the first day of each cycle, once every 3 weeks (21 days) for only 4 treatment cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chemotherapy
Description: Cisplatin: Administered by intravenous infusion during concurrent chemoradiotherapy at a dose of 30-40 mg/m² once weekly for only 5-6 treatment cycles; during sequential chemoradiotherapy, administered at 60-75 mg/m² on the first and second days of each cycle, once every 3 weeks (21 days) for only 4 treatment cycles.~Paclitaxel: Nab-paclitaxel administered by intravenous infusion at a dose of 135-175 mg/m² on the first day of each cycle, once every 3 weeks (21 days) for only 4 treatment cycles.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Pelvic external beam radiation therapy at a dose of 1.8 Gy per fraction or 2 Gy per day, 5 times per week, with a total dose of 45-50 Gy.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: radiotherapy
Description: Pelvic external beam radiation therapy at a dose of 1.8 Gy per fraction or 2 Gy per day, 5 times per week, with a total dose of 45-50 Gy.
Study: NCT06728215

Intervention type: DEVICE
Intervention: CRET 1
Description: Fisiowarm 7.0 and the new capacitive/resistive electrode, for 15' at a frequency of 300 KHz (Treated Group).

Intervention type: DEVICE
Intervention: CRET 2
Description: Classical methodology using the monopolar electrode Activ CT8 INDIBA® at a frequency of 448 KHz in both resistive and capacitive modes, for 10 min each mode with two different electrodes. (Control group).
Study: NCT05746208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 13C-Pyruvate
Description: Given IV
Study: NCT06544512

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: progressive relaxation exercise
Description: looking at pain and anxiety by practicing progressive relaxation exercises
Study: NCT05651828

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vismodegib 150 MG Oral Capsule
Description: Vismodegib is a hedgehog signalling pathway target agent. Participants will self-administer the standard 150 mg dose by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib 150 MG Oral Capsule
Description: Vismodegib is a hedgehog signalling pathway target agent. Participants will self-administer the standard 150 mg dose by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib 150 MG Oral Capsule
Description: Vismodegib is a hedgehog signalling pathway target agent. Participants will self-administer the standard 150 mg dose by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib 150 MG Oral Capsule
Description: Vismodegib is a hedgehog signalling pathway target agent. Participants will self-administer the standard 150 mg dose by mouth.
Study: NCT05812820

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LiveSpo DIA30
Description: LiveSpo® DIA 30 has a registration number: 6547/2019/ĐKSP issued by the Food Safety Department of the Ministry of Health in Vietnam

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LiveSpo CLAUSY
Description: LiveSpo® CLAUSY has a registration number: 4071/2021/ĐKSP issued by the Food Safety Department of the Ministry of Health in Vietnam

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: RO
Description: Aquafina's distilled water and reverse osmosis (RO) water, produce by PepsiCo, have both obtained ISO 9001:2015 and ISO 22000:2018 certifications, which are internationally recognized standards for quality management and food safety management systems, respectively.~The RO water ampoules are produced using a similar process as the LIVESPO DIA30/CLAUSY but contain 5ml of high-quality distilled water from Aquafina in an opaque plastic bottle
Study: NCT01446120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH-Insulin Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin loaded Orally Dissolved Films (insulin-ODF
Study: NCT05873478

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: The HIIT sessions ranging from 4-12 minutes in duration for 8 weeks in which three sessions will be conducted each week (weeks 1-3: 4 minutes; weeks 4-6: 8 minutes; weeks 7-8: 12 minutes respectively), with a work to rest ratio of 30sec: 10sec, as mention in table 1. Experimental group/HIT group engaged in their HIIT sessions (inclusive of a short warm-up activity including dynamic exercises i.e., walking/running, 8-10 minutes of HIIT and cool down which include static exercises i.e., shoulder and hip muscle stretches). Session duration and intensity are increased with weekly progression in intervention groups. The high resistance training sessions was be delivered by the researcher to HIT group
Study: NCT05588258

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Participants were given the 10% urea cream purchased in pharmacy or supermarket as appropriate after randomisation and their foot skin quality was assessed by validated questionnaire.
Description: Participants agreed to the interventions after allocation to each arm according to randomisation and after signing an informed consent form. The creams tested in this study provided to participants are authorised for sale within the European Union but are not considered drugs or medical devices. The main purpose of the interventions was based on the care and assessment of the quality of the skin of the participants' feet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Participants were given the 10% urea cream purchased in pharmacy or supermarket as appropriate after randomisation and their foot skin quality was assessed by validated questionnaire.
Description: Participants agreed to the interventions after allocation to each arm according to randomisation and after signing an informed consent form. The creams tested in this study provided to participants are authorised for sale within the European Union but are not considered drugs or medical devices. The main purpose of the interventions was based on the care and assessment of the quality of the skin of the participants' feet.
Study: NCT05717998

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Intervention: Computed Tomography
Description: Undergo cardiac PET/CT

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging of the Heart
Description: Undergo CMR

Intervention type: PROCEDURE
Intervention: Positron Emission Tomography
Description: Undergo cardiac PET/CT
Study: NCT05807867

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WMM-based intersectional stigma intervention
Description: Intervention components consist of:~1. psychoeducation: facilitating the achievement of good womanhood by adhering to psychiatric medications and ART post-discharge~2. cognitive restructuring to challenge stereotypes: involves reframing psychiatric and ART adherence postdischarge as enacting 'good womanhood' by countering stereotypes of being unable to care for the family or be a suitable marriage partner~3. Coping skills for discrimination: promoting safe disclosure of SMI and/or HIV status to facilitate psychiatric and ART adherence post-discharge.~Note: enhancing skills for discrimination sessions for women and family members are provided when female participants transition to outpatient care, thus enabling practice of skills in community-based situations. Intervention closes with a ceremony intended to convey WMM by bestowal of ceremonial shawls. The family member version will follow the same format, but each component will be covered in one session (3 sessions total).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention placebo control
Description: To isolate intervention effects, our attention control is designed to mimic all salient features of the WMM-based intervention (i.e., group format, co-leaders, duration, inpatient followed by community location) except for the WMM stigma content.
Study: NCT04891172

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti COVID 19 Intravenous Immunoglobulin (C-IVIG)
Description: Intervention arm will receive single dose of 0.15g/kg C-IVIG. This will be infused within period of 16 hours intravenously. Additionally, all participants will receive same standard care.~Standard Care as per hospital protocol, which may include:~Airway support, Anti-Viral medication, Antibiotics, Fluid Resuscitation, Hemodynamic Support, Steroids, Painkillers, Anti-Pyretics, anti coagulant
Study: NCT04892069

Intervention type: DRUG
Intervention: Insulin Degludec/Insulin Aspart
Description: All patients have been treated at the discretion of the treating physician in accordance with the Ryzodeg® label in Lebanon. Decision to initiate treatment with commercially available Ryzodeg® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
Study: NCT05182944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A：non-pCR patients
Description: After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, non-pCR patients adjuvant treatment（2-4 cycles Camrelizumab+Albumin Paclitaxel+Cisplatin and Camrelizumab maintenance treatment）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B：non-pCR patients
Description: After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, non-pCR patients adjuvant treatment（Camrelizumab maintenance treatment）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A：pCR patients
Description: After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, pCR patients adjuvant treatment（Camrelizumab maintenance treatment）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B：pCR patients
Description: After 2 cycles of neoadjuvant therapy（Camrelizumab+Albumin Paclitaxel+Cisplatin）, pCR patients adjuvant treatment（Best Supportive Care）~Camrelizumab, 200 mg，Intravenous injection，q3W continuous medication Albumin Paclitaxel, 125 mg/m2, Intravenous injection d1,8 q3W continuous medication Cisplatin: 75mg/m2, Intravenous injection,d1, q3W continuous medication
Study: NCT05043740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repatha or Praluent
Description: Evolocumab (Repatha®) 140 mg or Alirocumab (Praluent) 75mg every two weeks, first subcutaneous injection at the time of randomization, followings during 12 months
Study: NCT04956211

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal therapy
Description: Patients will receive a standard regimen of scaling and root planing of the root surfaces under local analgesia (depending on the severity in one or two sessions within 2 days) with curettes and ultrasonic instruments.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal therapy
Description: Patients will receive a standard regimen of scaling and root planing of the root surfaces under local analgesia (depending on the severity in one or two sessions within 2 days) with curettes and ultrasonic instruments.
Study: NCT06290986

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pyrocardan® implant
Description: Biconcave-shaped CMC-1 interposition implant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ligament reconstruction and tendon interposition (LRTI)
Description: Weilby slightly modified as described by Burton and Pellegrini
Study: NCT05180331

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Application to Prevent Suicide (MAPS)
Description: Safety Planning Intervention, ecological momentary intervention smartphone app system, and bidirectional communication with study clinician.
Study: NCT05550545

Intervention type: OTHER
Intervention: cohort study
Description: Please note that this is an observational study; not applicable
Study: NCT04533178

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: soft spinal brace
Description: Use of a soft spinal brace 16 hours per day during the 6 week treatment period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resting from all sports activities
Description: Resting from all sports activities

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resting from all sports activities
Description: Resting from all sports activities
Study: NCT05116553

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SDT
Description: Standard 2 SDT (Self Determination Theory) psychological interviews.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SDT
Description: Standard 2 SDT (Self Determination Theory) psychological interviews.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APP + CA
Description: An APP with a CA (Conversational Agent).
Study: NCT06071416

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral sinus floor augmentation
Description: maxillary sinus floor augmentation by lateral approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral sinus floor augmentation
Description: maxillary sinus floor augmentation by lateral approach

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biphasic Calcium Phosphate
Description: appliaction of BCP bone substitute

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biphasic Calcium Phosphate
Description: appliaction of BCP bone substitute

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Injectable platlets rich fibrin
Description: centrifuge 10 ml of patient blood to get I-PRF that applied to the bone substitute
Study: NCT04621331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: HIF-PH inhibitor for treatment of anemia in CKD
Study: NCT04861142

Intervention type: DRUG
Intervention: Anti-osteoporotic medication( alendronate or denosumab)
Description: Initiation of anti-osteoporotic medication (alendronate or denosumab)

Intervention type: DRUG
Intervention: Anti-osteoporotic medication( alendronate or denosumab)
Description: Initiation of anti-osteoporotic medication (alendronate or denosumab)
Study: NCT04710121

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Glasses
Description: Virtual Reality Glasses (VRG), one of the methods of distracting attention; widely used in clinical medical care to relieve symptoms by providing the opportunity to create therapeutic environments for the evaluation and treatment of medical conditions. Virtual reality is a computer simulation technique that enables individuals to hear and feel the sounds and corresponding stimuli accompanying the visual image through headphones. The most basic feature that distinguishes virtual reality (VR) glasses from similar applications is that it gives individuals a real feeling. VR has helped to distract patients from mental processing and reduce the amount of pain. Virtual reality glasses, which are inexpensive to apply and use, do not cause side effects, and can be used in the recovery of the individual, are an intervention that can be preferred in nursing practices.
Study: NCT06029764

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: extended one-level interbody fusion
Description: For patients who have vacuum signs in the intervertebral disc adjacent to the surgical segment but are asymptomatic and not unstable, the intervertebral fusion surgery is extended to one segment and followed up immediately after surgery, 3 months, 6 months, and annually within 1 to 5 years. Take lumbar spine MR to determine the degree of degeneration progression of adjacent segments and whether revision surgery is needed. Take X-rays of the lumbar spine in frontal and lateral + flexion and extension positions, and CT-three-dimensional reconstruction to judge the bony fusion of the intervertebral fusion.
Study: NCT05802888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracycline 500mg tid
Description: Amoxicillin 1000mg bid +Tetracycline 500mg tid +Bismuth+Esomeprazole 40mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline 500mg qid
Description: Amoxicillin 1000mg bid +Tetracycline 500mg qid +Bismuth+Esomeprazole 40mg bid
Study: NCT06238414

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early psychotherapeutic intervention
Description: The case group will receive an 8-session early psychological intervention The intervention consists of eight face-to-face sessions that include techniques from the dialectical behavioral (DBT), mentalization based therapy orientation (MBT), and narrative approach, concretely an adaptation from the ASSIP therapy. The sessions will be conducted by a clinical psychologist with expertise in psychotherapy. There will be two 60-minutes sessions per week.
Study: NCT05016518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm I (Propofol group)
Description: Propfol group will be started and maintained total intravenous anesthesia with propofol and remifentanil .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm II (Remimazolam group)
Description: Remimazolam group will be started and maintained total intravenous anesthesia with remimazolam and remifentanil.
Study: NCT06165302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: 12 weeks of prescribed exercise intervention.
Study: NCT04929275

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Enhanced recovery program
Description: 12 items of program (preoperative, peroperative postoperative) according to the enhanced recovery after surgery society
Study: NCT06043466

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CEA-targeted CAR-T cells
Description: Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.
Study: NCT04813523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection [Keytruda]
Description: Neoadjuvant period: pembrolizumab 200mg IV, Q3W with three cycles. Adjuvant period: pembrolizumab 200 mg IV, Q3W, up to one year, which should be performed within 3-6 weeks after surgery.
Study: NCT04987047

Intervention type: BIOLOGICAL
Intervention: Blood collection
Description: A blood sample will be collected at enrollment to perform pharmacogenetics analyses.

Intervention type: BIOLOGICAL
Intervention: Blood collection
Description: A blood sample will be collected at enrollment to perform pharmacogenetics analyses.

Intervention type: OTHER
Intervention: Questionnaires
Description: Several questionnaires will be filled by the participants or by the clinicians at every study visits: Hospital anxiety depression scale (HAD), Post Traumatic Stress Disorder Checklist for DSM-5 (PCL-5), Quick inventory of depressive symptomatology - self rated (QiDS), Beck's Anxiety Inventory (BAI), World Health Organization Quality Of Life (WHOQOL-BREF), EuroQol Group questionnaire (EQ5D), Frequency, intensity, burden of side effects rating (FIBSER), Udvalg for Kliniske Undersøgelser - Side Effects Rating Scale - for Patients (UKU-SERS-PAT), Clinical Global impression (CGI), Montgomery and Asberg Depression Rating Scale (MADRS).

Intervention type: OTHER
Intervention: Questionnaires
Description: Several questionnaires will be filled by the participants or by the clinicians at every study visits: Hospital anxiety depression scale (HAD), Post Traumatic Stress Disorder Checklist for DSM-5 (PCL-5), Quick inventory of depressive symptomatology - self rated (QiDS), Beck's Anxiety Inventory (BAI), World Health Organization Quality Of Life (WHOQOL-BREF), EuroQol Group questionnaire (EQ5D), Frequency, intensity, burden of side effects rating (FIBSER), Udvalg for Kliniske Undersøgelser - Side Effects Rating Scale - for Patients (UKU-SERS-PAT), Clinical Global impression (CGI), Montgomery and Asberg Depression Rating Scale (MADRS).

Intervention type: OTHER
Intervention: Cognitive test battery (optional)
Description: For patients participating in the ELAN ancillary study : the participants will undergo a battery of neurocognitive tests assessing motivation (élan vital in French).

Intervention type: OTHER
Intervention: Cognitive test battery (optional)
Description: For patients participating in the ELAN ancillary study : the participants will undergo a battery of neurocognitive tests assessing motivation (élan vital in French).
Study: NCT05866913

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sciatic nerve slippage.
Description: Sciatic nerve slippage.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Passive stretching of the hamstring muscles.
Description: Passive stretching of the hamstring muscles.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: passive shoulder mobilization.
Description: passive shoulder mobilization.
Study: NCT06293833

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose CT scan
Description: Participants get an annual low-dose CT scan in UZA

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation
Description: Smoking cessation campagnes